Target Price | AUD23.48 |
Price | AUD11.65 |
Potential |
101.51%
register free of charge
|
Number of Estimates | 7 |
7 Analysts have issued a price target Clinuvel Pharmaceutical 2026 .
The average Clinuvel Pharmaceutical target price is AUD23.48.
This is
101.51%
register free of charge
AUD39.11
235.73%
register free of charge
AUD14.14
21.37%
register free of charge
|
|
A rating was issued by 10 analysts: 8 Analysts recommend Clinuvel Pharmaceutical to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Clinuvel Pharmaceutical stock has an average upside potential 2026 of
101.51%
register free of charge
|
Jun '25 |
2026 Estimates |
|
---|---|---|
Revenue Million AUD | 95.02 | 103.80 |
0.50% | 9.24% | |
EBITDA Margin | 49.37% | 49.95% |
16.51% | 1.18% | |
Net Margin | 38.07% | 39.45% |
2.00% | 3.64% |
8 Analysts have issued a sales forecast Clinuvel Pharmaceutical 2026 . The average Clinuvel Pharmaceutical sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Clinuvel Pharmaceutical EBITDA forecast 2026. The average Clinuvel Pharmaceutical EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Clinuvel Pharmaceutical Analysts have issued a net profit forecast 2026. The average Clinuvel Pharmaceutical net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Jun '25 |
2026 Estimates |
|
---|---|---|
Earnings Per Share AUD | 0.72 | 0.82 |
2.86% | 13.89% | |
P/E | 14.26 | |
EV/Sales | 3.26 |
8 Analysts have issued a Clinuvel Pharmaceutical forecast for earnings per share. The average Clinuvel Pharmaceutical EPS is
This results in the following potential growth metrics and future valuations:
Clinuvel Pharmaceutical...
Analyst | Rating | Action | Date |
---|---|---|---|
WILSONS |
Locked
➜
Locked
|
Locked | Sep 16 2025 |
JEFFERIES |
Locked
➜
Locked
|
Locked | Sep 08 2025 |
BELL POTTER SECURITIES |
Locked
➜
Locked
|
Locked | Sep 04 2025 |
MOELIS AUSTRALIA SECURITIES |
Locked
➜
Locked
|
Locked | Aug 29 2025 |
WILSONS |
Locked
➜
Locked
|
Locked | Jul 18 2025 |
WILSONS |
Locked
➜
Locked
|
Locked | Jul 17 2025 |
JEFFERIES |
Locked
➜
Locked
|
Locked | Jul 17 2025 |
Analyst Rating | Date |
---|---|
Locked
WILSONS:
Locked
➜
Locked
|
Sep 16 2025 |
Locked
JEFFERIES:
Locked
➜
Locked
|
Sep 08 2025 |
Locked
BELL POTTER SECURITIES:
Locked
➜
Locked
|
Sep 04 2025 |
Locked
MOELIS AUSTRALIA SECURITIES:
Locked
➜
Locked
|
Aug 29 2025 |
Locked
WILSONS:
Locked
➜
Locked
|
Jul 18 2025 |
Locked
WILSONS:
Locked
➜
Locked
|
Jul 17 2025 |
Locked
JEFFERIES:
Locked
➜
Locked
|
Jul 17 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.